Oxyla

Oxytocin

Antepartum: Induction or enhancement of labor. Adjunctive therapy for management of incomplete, inevitable or missed abortion. Postpartum: Caesarean section. Prevention & treatment of postpartum uterine atony & hemorrhage.

IV infusion Induction or enhancement of labor Initially, 1-4 milliunits/min (2-8 drops/min). May be increased gradually at intervals not <20 min & increments of not >1-2 milliunits/min until contraction pattern similar to normal labor is established. Pregnancy near term <10 milliunits/min (20 drops/min), max: 20 milliunits/min (40 drops/min). Incomplete, inevitable or missed abortion 5 IU or 5-10 IU IM, if necessary followed by IV infusion at a rate of 20-40 milliunits/min. Caesarean section 5 IU immediately after delivery. Prevention of postpartum uterine hemorrhage 5 IU or 5-10 IU IM after delivery of the placenta. Treatment of postpartum uterine hemorrhage 5 IU or 5-10 IU IM, followed in severe cases by IV infusion of 5-20 IU in 500 mL of electrolyte-containing diluent, but at the rate necessary to control uterine atony.

Hypersensitivity. Hypertonic uterine contractions or fetal distress. Significant cephalopelvic disproportion, fetal malpresentation, placenta & vasa praevia, placental abruption, cord presentation of prolapse, overdistension or impaired resistance of the uterus to rupture as in multiple pregnancy, polyhydramnios, grand multiparity & in the presence of a uterine scar resulting from major surgery including classical caesarean section. Do not administer w/in 6 hr after vag prostaglandins have been given.

Do not use for prolonged periods in case of oxytocin-resistant uterine inertia, severe pre-eclamptic toxemia or severe CV disorders. Patients w/ pre-disposition to myocardial ischemia due to pre-existing CV disease (eg, hypertrophic cardiomyopathy, vascular heart disease &/or ischemic heart disease including coronary artery vasospasm). Long QT syndrome or related symptoms. Do not administer by SC, IM or IV bolus inj when given for induction & enhancement of labor. Monitor fetal heart rate & uterine motility (frequency, strength & duration of contractions). Borderline cephalopelvic disproportion, secondary uterine inertia, mild or moderate degrees of pregnancy-induced HTN of cardiac disease, patients >35 year or w/ history of lower-uterine-segment caesarean section. Risk of postpartum disseminated intravascular coagulation (DIC). Avoid tumultuous labor in case of fetal death in utero &/or in the presence of meconium-stained amniotic fluid. Water intoxication. Severe renal impairment.

Headache; tachycardia, bradycardia; nausea, vomiting.

Potentiated uterine action of prostaglandins & analogues. Potentially arrhythmogenic in patients w/ other risk factors for Torsades de pointes eg, drugs which prolong the QT interval or in patients w/ history of long QT syndrome. May diminish uterotonic effects w/ inhalation anesth (eg, cyclopropane, halothane, sevoflurane, desflurane). May enhance vasopressor effects of vasoconstrictors, sympathomimetics, local anesth. May potentiate pressor effects of sympathomimetic vasoconstrictor agents during or after caudal block anesth.

Drugs Acting on the Uterus

H01BB02 - oxytocin ; Belongs to the class of oxytocin and analogues. Used in posterior pituitary lobe hormone preparations.

Rx